Prognostic and Predictive Value of
LIV1
SLC39A6
ZIP6
antibody–drug conjugates
breast cancer
expression
survival
zinc transporter protein
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
14 Mar 2023
14 Mar 2023
Historique:
received:
10
02
2023
revised:
09
03
2023
accepted:
10
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
LIV1 is a transmembrane protein that may become a new therapeutic target through the development of antibody-drug conjugates (ADCs). Few studies are available regarding the assessment of We analyzed LIV1 expression was associated with good-prognosis features and with longer DFS and OS in multivariate analysis. However, patients with high These results may provide novel insights into the clinical development and use of LIV1-targeted ADCs by identifying prognostic and predictive value of
Sections du résumé
BACKGROUND
BACKGROUND
LIV1 is a transmembrane protein that may become a new therapeutic target through the development of antibody-drug conjugates (ADCs). Few studies are available regarding the assessment of
METHODS
METHODS
We analyzed
RESULTS
RESULTS
LIV1 expression was associated with good-prognosis features and with longer DFS and OS in multivariate analysis. However, patients with high
CONCLUSIONS
CONCLUSIONS
These results may provide novel insights into the clinical development and use of LIV1-targeted ADCs by identifying prognostic and predictive value of
Identifiants
pubmed: 36986799
pii: pharmaceutics15030938
doi: 10.3390/pharmaceutics15030938
pmc: PMC10058875
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ligue Nationale Contre le Cancer
ID : EL2022/FB
Organisme : Association Ruban Rose
ID : Prix Ruban Rose 2020, FB
Références
Ann Oncol. 2017 Apr 1;28(4):769-776
pubmed: 27998973
Biomedicines. 2022 May 05;10(5):
pubmed: 35625809
Mol Cancer Ther. 2014 Dec;13(12):2991-3000
pubmed: 25253783
Cancer Epidemiol Biomarkers Prev. 2022 Dec 5;31(12):2136-2147
pubmed: 36129803
Ann Oncol. 2019 Mar 1;30(3):365-373
pubmed: 30715161
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
Int J Cancer. 2005 Dec 20;117(6):961-73
pubmed: 15986450
PLoS One. 2011;6(11):e27656
pubmed: 22110708
Br J Cancer. 2018 Nov;119(11):1383-1391
pubmed: 30353048
Oncotarget. 2016 Nov 1;7(44):71198-71210
pubmed: 27589570
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Biosci Rep. 2020 Aug 28;40(8):
pubmed: 32744318
Clin Cancer Res. 2018 Jun 1;24(11):2517-2529
pubmed: 29581135
Future Oncol. 2020 Apr;16(12):705-715
pubmed: 32223649
Lancet. 2023 Jan 14;401(10371):105-117
pubmed: 36495879
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Ann Transl Med. 2022 Jun;10(11):647
pubmed: 35813338
Cancer J. 2022 Nov-Dec 01;28(6):436-445
pubmed: 36383906
Int J Cancer. 2005 Sep 1;116(3):340-50
pubmed: 15818618
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Mol Cell Endocrinol. 1996 Nov 29;124(1-2):71-7
pubmed: 9027326
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Biometals. 2001 Sep-Dec;14(3-4):251-70
pubmed: 11831460
Breast Cancer Res Treat. 2021 Oct;189(3):621-630
pubmed: 34453638
CA Cancer J Clin. 2022 Mar;72(2):165-182
pubmed: 34767258
J Natl Cancer Inst. 2005 Jul 20;97(14):1023-5
pubmed: 16030294
Biochem J. 2013 Oct 15;455(2):229-37
pubmed: 23919497
Cancer Res. 2004 Feb 15;64(4):1522-33
pubmed: 14973112
Int J Mol Sci. 2023 Jan 09;24(2):
pubmed: 36674777
Ann Oncol. 2020 Dec;31(12):1623-1649
pubmed: 32979513
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Endocr Relat Cancer. 2006 Dec;13(4):1109-20
pubmed: 17158757
Cancer Biol Med. 2020 Aug 15;17(3):612-625
pubmed: 32944394
Cancers (Basel). 2021 Jun 09;13(12):
pubmed: 34207890
Explor Target Antitumor Ther. 2022 Apr 26;3(2):224-239
pubmed: 35591900
Oncotarget. 2016 Sep 13;7(42):68012-68022
pubmed: 27634906
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Mol Cancer Ther. 2022 Jul 5;21(7):1227-1235
pubmed: 35534238
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166